Vertex quarterly loss narrows

NEW YORK, July 31 (Reuters) - Vertex Pharmaceuticals Inc (VRTX.O) reported a smaller second-quarter loss on Thursday on higher collaboration revenue and lower costs associated with development of its experimental hepatitis C drug.

The Cambridge, Massachusetts-based biotechnology company posted a net loss of $91.3 million, or 66 cents per share, compared with a loss of $117.8 million, or 91 cents per share, a year ago. (Reporting by Bill Berkrot, editing by Leslie Gevirtz)